{
    "clinical_study": {
        "@rank": "111164", 
        "brief_summary": {
            "textblock": "To compare AS-101 dosing schedules (once a week;  3 times a week; 5 times a week; or 5 times\n      per week on alternate weeks) on the effect on clinical immunology and virus burden in AIDS\n      or AIDS related complex (ARC) patients."
        }, 
        "brief_title": "An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Standard therapy for infections.\n\n          -  Acyclovir.\n\n          -  Ganciclovir.\n\n          -  Allowed only with permission of Wyeth-Ayerst medical monitor:\n\n          -  Zidovudine (AZT).\n\n          -  Immunomodulators.\n\n          -  Specific therapy for malignancies (including Kaposi's sarcoma).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  Evidence of severe liver dysfunction (serum albumin < 3 g/dl, SGOT or SGPT > 5 x\n             upper limit of normal, prothrombin time > 15 seconds), or gastrointestinal, renal,\n             respiratory, endocrine, hematologic, cardiovascular system abnormalities or\n             psychiatric disorder other than abnormalities secondary to AIDS or AIDS related\n             complex (ARC).\n\n          -  Evidence of AIDS-related central nervous system involvement.\n\n          -  Disseminated Kaposi's sarcoma.\n\n        Concurrent Medication:\n\n        Excluded without permission of Wyeth-Ayerst medical monitor:\n\n          -  Zidovudine (AZT).\n\n          -  Immunomodulators.\n\n          -  Specific therapy for malignancies (including Kaposi's sarcoma).\n\n        Patients with the following are excluded:\n\n          -  Evidence of major system abnormalities other than abnormalities secondary to AIDS or\n             AIDS related complex.\n\n          -  Concomitant conditions as specified in Patient Exclusion Co-existing Conditions.\n\n          -  Unlikely or unable to comply with the requirements of the protocol.\n\n        Prior Medication:\n\n        Excluded within 4 weeks of study entry:\n\n          -  Systemic antiviral agents.\n\n          -  Immunosuppressive agents.\n\n          -  Immune stimulators such as BCG vaccine, isoprinosine, or other immunomodulators.\n\n        Patients must:\n\n          -  Have a diagnosis of AIDS or AIDS related complex (ARC).\n\n          -  Demonstrate intolerance or refusal to take zidovudine (AZT).\n\n          -  Provide written informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002266", 
            "org_study_id": "045B", 
            "secondary_id": "753A-103-US"
        }, 
        "intervention": {
            "intervention_name": "AS-101", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ammonium trichloro(dioxoethylene-O,O'-)tellurate"
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "ammonium trichloro(dioxoethylene-O,O'-)tellurute"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tucson", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85724"
                }, 
                "name": "Univ of Arizona / Health Science Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002266"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wyeth is now a wholly owned subsidiary of Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1990"
    }, 
    "geocoordinates": {
        "Univ of Arizona / Health Science Ctr": "32.222 -110.926"
    }
}